SYDNEY, May 15, 2019 – George Clinical, a global scientifically-backed clinical research organization (CRO), has significantly expanded its capabilities in Taiwan having been granted a license to import drugs into the country for clinical trials on behalf of sponsors. The development will be particularly helpful for small to mid-sized clinical trial clients who do not […]
Read MoreSydney, Australia, April 24, 2019 – EPS International Holdings Co., Ltd. (HQ: Tokyo, Japan; Representative Director and President: Hisashi Tanaka; “EPSI” hereafter) and George Clinical Pty Ltd (HQ: Sydney, Australia; Executive Chairman: Glenn Kerkhof; “George Clinical” hereafter) announced today that they have reached an agreement on a strategic partnership that will enhance their combined service offerings […]
Read MoreNoxopharm, a clinical-stage Australian drug development company currently working with George Clinical, is seeking to establish Veyonda®, an innovative dosage formulation of the experimental anti-cancer drug idronoxil, as “an essential adjunct to all forms of radiotherapy in the treatment of prostate cancer, both late-stage and early-stage prostate cancer,” according to an announcement last week. Through […]
Read More
OneOncology, a national partnership of community oncologists, recently announced that Lee Schwartzberg, MD, FACP, a member of the George Clinical scientific leadership committee, has been named Chief Medical Officer (CMO). According to OneOncology, the CMO position “provides a dynamic link between OneOncology and its physician partners, demonstrating the shared, foundational commitment to a physician-driven, data-driven, technology-powered, […]
Read More
ISN World Congress of Nephrology will be live streaming “Late Breaking Clinical Trials” from WCN 2019. The purpose of the webcast is to give the worldwide nephrology community in-depth understanding of three major nephrology studies, including the CREDENCE study for which George Clinical plays a critical role. The session will be streamed live from […]
Read MoreGeorge Clinical, a global scientifically backed clinical research organization, (CRO) has expanded its footprint in Asia with the addition of a new presence in Singapore. The new office and entity in Singapore, which was established in July, were requisites for George Clinical to act as a local clinical trial sponsor for the firm’s international client […]
Read More
OVERLAND PARK, KS, March 6, 2019 George Clinical, a leading Asia-Pacific based clinical research organization (CRO) with global capabilities, today announced that Dr. Maria Ali has been promoted to Chief Medical Officer to be based out of Raleigh, North Carolina. This move further solidifies the strategic growth of George Clinical throughout North America and recognizes […]
Read More[Sydney, Australia] George Clinical congratulates its parent company, The George Institute for Global Health for securing $12 million from the National Health and Medical Research Council (NHMRC), Australia’s peak funding body for medical research. These grants will support The Institute’s scientific leaders to improve the lives of people living with chronic kidney disease, septic shock […]
Read MoreGeorge Clinical congratulates its parent company, The George Institute for Global Health for securing a project grant that could transform the treatment of chronic kidney disease (CKD) globally and benefit millions of people globally. The $5.5 million awarded by the National Health and Medical Research Council (NHMRC), Australia’s peak funding body for medical research, is […]
Read MoreGeorge Clinical welcomes the recognition of Professor Craig Anderson as profiled in the premier medical journal The Lancet which identified him as “a front runner in stroke research”. “It is our engagement with scientific leaders, such as Professor Anderson, that sets George Clinical apart from other CROs,” said Philip Gregory, Managing Director, China. “The Lancet […]
Read More
customerservice@georgeclinical.com
Profits from George Clinical support the work of The George Institute for Global Health.
Join our Mailing List
